Simethicone otilonium bromide chewable tablets and preparing method thereof

A technology of otilonium bromide and simethicone, which is applied in pharmaceutical formulations, active ingredients of silicon compounds, drug delivery, etc., can solve the problems of no research reports on simethicone and otilonium bromide chewable tablets, and no product listing, etc. Good application prospects, reasonable prescription design, smooth and beautiful effect

Inactive Publication Date: 2015-04-22
SOUTHWEST UNIVERSITY
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] But so far, there are no research reports on the combination of simethicone and otilonium bromide prepared into chewable tablets at home and abroad, and no related products are listed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Simethicone otilonium bromide chewable tablets and preparing method thereof
  • Simethicone otilonium bromide chewable tablets and preparing method thereof
  • Simethicone otilonium bromide chewable tablets and preparing method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Simethicone Otilonium Bromide Chewable Tablets, the specific formula is as follows:

[0027]

[0028] Above-mentioned formula is made 1000 Simethicone otilonium bromide chewable tablets, and preparation method comprises the steps:

[0029] a. The solid components (otilonium bromide, cornstarch, glucose, magnesium stearate, sodium saccharin) in the formula are pulverized into fine powders with a particle size of more than 80 mesh respectively; the PVP-K30 of the formula quantity is mixed with 10 % PVP-K30 ethanol (50%) solution;

[0030] b. Take the formula quantity of simethicone and mix evenly with cornstarch; then mix evenly with the formula quantity of otilonium bromide, glucose and sodium saccharin; add 10% PVP-K30 ethanol solution to make soft material, pass through a 20-mesh sieve to granulate , dried at 40°C, and then passed through a 20-mesh sieve for granulation;

[0031] c. Spray evenly the essence of the formula amount on the surface of the dry granules ...

Embodiment 2

[0036] Simethicone Otilonium Bromide Chewable Tablets, the specific formula is as follows:

[0037]

[0038] Above-mentioned formula is made 1000 Simethicone otilonium bromide chewable tablets, and preparation method comprises the steps:

[0039] a. The solid components (otilonium bromide, cornstarch, sucrose, mannitol, magnesium stearate, aspartame) in the formula are pulverized into fine powders with particle size above 80 mesh respectively; -K30 is formulated with 10% PVP-K30 ethanol (50%) solution;

[0040] b. Take the simethicone of formula quantity and mix evenly with cornstarch; Mix evenly with otilonium bromide, mannitol, sucrose, aspartame again with formula quantity; Add 10% PVP-K30 ethanol solution to make soft material, pass Granulate with a 20-mesh sieve, dry at 40°C, and pass through a 20-mesh sieve for granulation;

[0041] c. Spray the essence of the prescribed amount evenly on the surface of the dry granules arranged in step b, seal it with a sealed bag f...

Embodiment 3

[0045] Simethicone Otilonium Bromide Chewable Tablets, the specific formula is as follows:

[0046]

[0047] Above-mentioned formula is made 1000 Simethicone otilonium bromide chewable tablets, and preparation method comprises the steps:

[0048] a. The solid components (otilonium bromide, microcrystalline cellulose, mannitol, magnesium stearate, micropowder silica gel, sodium saccharin) in the formula are pulverized into fine powders with a fineness of more than 80 mesh respectively; The PVP-K30 is formulated into 10% PVP-K30 ethanol (50%) solution;

[0049] b. Mix the simethicone and microcrystalline cellulose in the prescribed amount; then mix evenly with the prescribed amount of otilonium bromide, mannitol, and sodium saccharin; add 10% PVP-K30 ethanol solution to make a soft material, and pass through a 20-mesh sieve Granulate, dry at 50°C, and pass through a 20-mesh sieve for granulation;

[0050] c. Spray the essence in the formula amount evenly on the surface of t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
hardnessaaaaaaaaaa
hardnessaaaaaaaaaa
Login to view more

Abstract

The invention discloses simethicone otilonium bromide chewable tablets and a preparing method of the simethicone otilonium bromide chewable tablets. The simethicone otilonium bromide chewable tablets comprise, by mass, 12.5 parts of simethicone, 4 parts of otilonium bromide, 10-40 parts of adsorbent, 25-75 parts of filler, 0.2-10 parts of adhesive, 0.2-5.0 parts of lubricant, 0.5-10 parts of corrigent, 0.05-0.5 part of aromatic and 1.5-7.5 parts of moisture sealer coating materials. According to the simethicone otilonium bromide chewable tablets, the formula is reasonable, the cost is low, and the preparing method is simple and suitable for industrial production. The prepared tablets are good in taste, the surfaces of the tablets are smooth and attractive, the tablets are even in color, appropriate in hardness, stable in quality, convenient to take and carry, and particularly suitable for the elderly, children and patients who cannot swallow solid preparations, the compliance of the patients is improved, and the simethicone otilonium bromide chewable tablets have good application prospects to treatment of the irritable bowel syndrome due to various reasons, especially the irritable bowel syndrome accompanied with abdominal distension and stomachache.

Description

technical field [0001] The invention belongs to the field of pharmacy, and in particular relates to simethicone otilonium bromide chewable tablets, and also relates to a preparation method of the chewable tablets. Background technique [0002] Gastrointestinal dysfunction (WSN) is a general term for a group of gastrointestinal syndromes. Clinically, there are not only gastrointestinal manifestations such as epigastric discomfort, anorexia, abdominal distension, abdominal pain, diarrhea, belching, acid reflux, nausea, vomiting, and constipation, but also systemic neurosis manifestations, such as insomnia, dreaminess, and forgetfulness. , physical fatigue, inattention, palpitations, chest tightness, headache, dizziness, spontaneous sweating, night sweats, etc., are common chronic and intractable diseases in clinical practice. The occurrence of WSN is often related to mental factors. Emotional disorders and thinking fatigue can cause the occurrence of WSN. The salient feature...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/695A61K9/36A61P1/00A61P29/00A61K31/245
Inventor 罗雷曾海春罗永煌王小红王兰周骆晓宏
Owner SOUTHWEST UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap